MODIFIZIERTE TGF-BETA2-OLIGONUKLEOTIDE

European patent · EP2978844 · In force

Register entry

Publication number
EP2978844
Application number
EP14713127
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 27, 2014
Published
Feb 3, 2016
Granted
Aug 12, 2020
Protection ends at the latest
Mar 26, 2034
Next annual fee due
Mar 31, 2027
IPC classes
C12N 15/113 (2010.01)
C07H 21/00 (2006.01)
A61K 31/713 (2006.01)
A61P 35/00 (2006.01)
A61P 37/00 (2006.01)
A61P 27/02 (2006.01)
Priority
EP 13161474 27.03.2013
EP 13173078 20.06.2013
EP 13199838 30.12.2013
PCT application
PCT/EP2014/056232 27.03.2014
PCT publication
WO2014/154843 02.10.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  4. Apr 1, 2023

    Change

    Published in Swissreg on 01.04.2023

  5. Aug 12, 2020

    Granted

    Published in Swissreg on 12.08.2020

Parties

Holder

ISARNA Therapeutics GmbH

Schellingstraße 109a, 80798 München, DE

Inventor

JASCHINSKI, Frank

82178 Puchheim, DE

JANICOT, Michel

B-1180 Brussels, BE

UHLMANN, Eugen

D-61479 Glashütten, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.